Have you or your loved ones been diagnosed with catheter-related infections?

You may be eligible to participate in a catheter-related infections clinical trial.

Have you or your loved ones been diagnosed with catheter-related infections? You may be eligible to participate in a catheter-related infections clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Catheter-related Infections Clinical Trial in Detroit MI
NCT02901717 | Phase 3 | Interventional

Have you or your loved ones been diagnosed with catheter-related infections?

You may be eligible to participate in a catheter-related infections clinical trial.

Have you or your loved ones been diagnosed with catheter-related infections? You may be eligible to participate in a catheter-related infections clinical trial.

Recruiting

Male & Female

12 Years +

This study is looking to recruit 144 Participants

This is a Phase 3, multi-center, randomized, open-label, assess-blind study to determine the efficacy and safety of MLT, a novel antibiotic lock therapy that combines minocycline with edetate disodium in 25% ethanol solution as an adjuctive therapy for the treatment of catheter-related or central line associated bloodstream infection (CRBSI/CLABSI). Approximately 144 subjects who have been diagnosed with CRBSI/CLABSI and who meet all necessary criteria for the study will be randomized in a 1:1 ratio to 1 of 2 treatment arms: - MLT Arm: Mino-Lok therapy; or - Control Arm: Antibiotic lock (±heparin). The antibiotic lock (ALT) should be comprised of the best available therapy at the sites based on standard institutional practices or recommendations from the Infectious Diseases Society of America (IDSA) guidelines.